Viewray (NASDAQ:VRAY) Shares Gap Up to $2.44

Viewray Inc (NASDAQ:VRAY) shares gapped up before the market opened on Friday . The stock had previously closed at $2.38, but opened at $2.44. Viewray shares last traded at $2.77, with a volume of 2,237,523 shares.

Several research firms recently weighed in on VRAY. BidaskClub raised shares of Viewray from a “strong sell” rating to a “sell” rating in a research report on Friday, June 5th. Oppenheimer reaffirmed a “buy” rating and set a $3.00 price objective on shares of Viewray in a research report on Tuesday, June 23rd. Cantor Fitzgerald assumed coverage on shares of Viewray in a report on Monday, June 15th. They set a “buy” rating and a $3.00 price target on the stock. Zacks Investment Research upgraded shares of Viewray from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Saturday, May 9th. Finally, BTIG Research restated a “hold” rating on shares of Viewray in a research report on Wednesday, June 3rd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $4.55.

The firm has a market cap of $408.30 million, a price-to-earnings ratio of -3.11 and a beta of 0.74. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.81 and a quick ratio of 3.87. The firm’s fifty day moving average is $2.23 and its 200-day moving average is $2.41.

Viewray (NASDAQ:VRAY) last released its earnings results on Thursday, July 30th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The firm had revenue of $14.22 million during the quarter, compared to analyst estimates of $5.81 million. Viewray had a negative net margin of 166.74% and a negative return on equity of 63.54%. As a group, equities research analysts anticipate that Viewray Inc will post -0.67 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in VRAY. Raymond James & Associates lifted its holdings in Viewray by 40.4% in the fourth quarter. Raymond James & Associates now owns 120,250 shares of the company’s stock valued at $507,000 after buying an additional 34,600 shares during the period. Credit Suisse AG raised its holdings in shares of Viewray by 56.5% during the fourth quarter. Credit Suisse AG now owns 62,386 shares of the company’s stock valued at $263,000 after purchasing an additional 22,523 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Viewray by 26.3% during the fourth quarter. Bank of New York Mellon Corp now owns 723,113 shares of the company’s stock valued at $3,051,000 after purchasing an additional 150,599 shares during the period. Marshall Wace LLP acquired a new position in shares of Viewray during the fourth quarter valued at about $50,000. Finally, Geode Capital Management LLC raised its holdings in shares of Viewray by 59.2% during the fourth quarter. Geode Capital Management LLC now owns 1,346,216 shares of the company’s stock valued at $5,681,000 after purchasing an additional 500,864 shares during the period. Institutional investors and hedge funds own 83.62% of the company’s stock.

About Viewray (NASDAQ:VRAY)

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Featured Story: What is meant by buying and selling pressure?

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.